Njenge-agonist ye-GLP-1, ilingisa imiphumela ye-physiological ye-GLP-1 ekhishwe ngokwemvelo emzimbeni.
Ukusabela ekuthathweni kwe-glucose, ama-neurons e-PPG ohlelweni lwezinzwa olumaphakathi (CNS) kanye namaseli e-L emathunjini akhiqiza futhi akhiphe i-GLP-1, i-hormone evimbela ama-gastrointestinal.
Ngemuva kokukhishwa, i-GLP-1 ivuselela ama-GLP-1R receptors kuma-pancreatic β-cell, okubangela uchungechunge lwezinguquko ze-metabolic ezibonakala ngokukhiqizwa kwe-insulin nokucindezelwa kokudla.
Ukukhiqizwa kwe-insulin kuholela ekwehleni okuphelele kwamazinga kashukela egazini, ukwehla kokukhiqizwa kwe-glucagon, nokuvimbela ukukhishwa kweglucose ezitolo ze-glycogen zesibindi. Lokhu kudala ukusutha, kuthuthukisa ukuzwela kwe-insulin, futhi ekugcineni kubangele ukuncipha kwesisindo.
Umuthi uvuselela ukukhiqizwa kwe-insulin ngendlela encike kushukela, ngaleyo ndlela wehlise ubungozi be-hypoglycemia. Ngaphezu kwalokho, kunemiphumela emihle yesikhathi eside ekusindeni, ukwanda, kanye nokukhiqizwa kabusha kwama-β-cell.
Ucwaningo lukhombisa ukuthi i-semaglutide ngokuyinhloko ilingisa imiphumela ye-GLP-1 ekhishwe emathunjini kunokuba ivela ebuchosheni. Lokhu kungenxa yokuthi ama-receptors amaningi e-GLP-1 ebuchosheni angaphandle kwebanga elisebenzayo lale mithi elawulwa ngohlelo. Naphezu kwesenzo sayo esiqondile esilinganiselwe kuma-receptors e-brain GLP-1, i-semaglutide isasebenza kakhulu ekwehliseni ukudla nesisindo somzimba.
Kubonakala kufeza lokhu ngokwenza kusebenze amanethiwekhi e-neuronal ohlelweni lonkana lwezinzwa, eziningi zazo okuyizimpokophelo zesibili ezingavezi ngokuqondile ama-GLP-1 receptors.
Ngo-2024, izinguqulo ezivunyiwe zentengiso ze-semaglutide zifakaOzempic, I-Rybelsus, futhiWegovyimijovo, yonke ithuthukiswe ngabakwaNovo Nordisk.
Isikhathi sokuthumela: Aug-18-2025